Clinical Trial Results:
A phase III assessor-blinded randomised parallel group multi-centre study to compare efficacy and safety of two r-hFSH formulations (AFOLIA and Gonal-f®) in women for assisted reproductive treatment
Summary
|
|
EudraCT number |
2010-019287-37 |
Trial protocol |
DE AT ES GB DK |
Global end of trial date |
31 Dec 2012
|
Results information
|
|
Results version number |
v1 |
This version publication date |
04 Mar 2016
|
First version publication date |
04 Mar 2016
|
Other versions |
v2 |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
FIN3001
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT01121666 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Finox AG
|
||
Sponsor organisation address |
Technikumstrasse 2, Burgdorf, Switzerland, 3401
|
||
Public contact |
Julian Jenkins, Finox AG, +41 34 426 11 11, info@finoxbiotech.com
|
||
Scientific contact |
Julian Jenkins, Finox AG, +41 34 426 11 11, info@finoxbiotech.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Interim
|
||
Date of interim/final analysis |
28 Sep 2012
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
31 Dec 2012
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
The purpose of this study is to show equivalence between AFOLIA and Gonal-f® with regard to the number of oocytes retrieved in women for assisted reproductive treatment
|
||
Protection of trial subjects |
Study Design:
This was a multi-centre, assessor-blind, comparative Phase 3 study with central patient randomization. After obtaining informed consent, patients were screened for eligibility for the study. The endogenous FSH production of eligible patients was down-regulated with a GnRH–agonist. After down-regulation of endogenous FSH, patients were randomised 2:1 to receive either AFOLIA or Gonal f daily. FSH in both groups was administered s.c. A starting dose of 150 IU/day was administered in both groups. Ovarian response was assessed by vaginal ultrasound on day 1, 6, 8, and on the day of hCG application, 16 days after start of treatment with r-hFSH at the latest. For patients’ safety serum E2 concentration was measured as well. After day 8 assessment, follicular development was monitored by vaginal ultrasound at 2-3 days interval. Patients received daily r-hFSH until at least 1 follicle reached a diameter of ≥18 mm and 2 additional follicles reached a diameter of ≥16 mm, but no longer than 16 days. At this time, hCG was given to trigger ovulation. Oocytes were removed and ICSI or IVF was done according to standard techniques. A maximum of two embryos were transferred 2 to 5 days after oocyte retrieval. Pregnancy rate was determined biochemically and clinically.
Criteria for Safety Evaluation:
- Adverse events
- Local and systemic adverse event pattern (incl. ovarian hyper stimulation syndrome (OHSS))
- Time to first Onset of OHSS
- Time to first Dose Reduction due to imminent OHSS
- Percentage of patients with dose reduction due to imminent OHSS
- Clinical laboratory tests
- Vital signs
- Physical examination / Health status
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
01 Jun 2010
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Spain: 52
|
||
Country: Number of subjects enrolled |
United Kingdom: 31
|
||
Country: Number of subjects enrolled |
Austria: 131
|
||
Country: Number of subjects enrolled |
Denmark: 112
|
||
Country: Number of subjects enrolled |
Germany: 35
|
||
Country: Number of subjects enrolled |
Switzerland: 11
|
||
Worldwide total number of subjects |
372
|
||
EEA total number of subjects |
361
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
372
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
||||||||||||||||
Recruitment
|
||||||||||||||||
Recruitment details |
Subjects were screened and enrolled at 15 centers in six European countries from July 2010 until April 2012 | |||||||||||||||
Pre-assignment
|
||||||||||||||||
Screening details |
Of 460 participants in this trial 88 were reported as screening failures prior the group assignment | |||||||||||||||
Period 1
|
||||||||||||||||
Period 1 title |
Overall study (overall period)
|
|||||||||||||||
Is this the baseline period? |
Yes | |||||||||||||||
Allocation method |
Randomised - controlled
|
|||||||||||||||
Blinding used |
Single blind | |||||||||||||||
Roles blinded |
Assessor [1] | |||||||||||||||
Arms
|
||||||||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||||||||
Arm title
|
AFOLIA-150 (Follitropin Alfa) | |||||||||||||||
Arm description |
Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days | |||||||||||||||
Arm type |
Experimental | |||||||||||||||
Investigational medicinal product name |
AFOLIA-150 (Follitropin alfa)
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Injection
|
|||||||||||||||
Routes of administration |
Subcutaneous use
|
|||||||||||||||
Dosage and administration details |
150IU per day subcutaneously for a maximum of 16 days
|
|||||||||||||||
Arm title
|
Gonal-f® (Follitropin Alfa) | |||||||||||||||
Arm description |
Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days. | |||||||||||||||
Arm type |
Active comparator | |||||||||||||||
Investigational medicinal product name |
Gonal-f® (Follitropin alfa)
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Injection
|
|||||||||||||||
Routes of administration |
Subcutaneous use
|
|||||||||||||||
Dosage and administration details |
150IU per day subcutaneously for a maximum of 16 days
|
|||||||||||||||
Notes [1] - The roles blinded appear inconsistent with a simple blinded trial. Justification: Blinding (masking) indicates that knowledge of the intervention assignments is hidden from participants, trial investigators, or assessors. The terminology single blind usually means that one of the three categories of individuals remains unaware of intervention assignments throughout the trial. A single-blind trial might also, confusingly, mean that the participant and investigator both know the intervention, but that the assessor remains unaware of it. |
||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
AFOLIA-150 (Follitropin Alfa)
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Gonal-f® (Follitropin Alfa)
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis sets
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
AFOLIA-150 (Follitropin Alfa) (Per Protocol Population)
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Per protocol | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days; Per Protocol Population
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
Gonal-f® (Follitropin Alfa) (Per Protocol Population)
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Per protocol | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days; Per Protocol Population
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
AFOLIA-150 (Follitropin Alfa) (2nd treatment cycle)
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Sub-group analysis | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days; Population with a second treatment cycle
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
Gonal-f® (Follitropin Alfa) (2nd treatment cycle)
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Sub-group analysis | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days; Population with a second treatment cycle
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
AFOLIA-150 (Follitropin Alfa)
|
||
Reporting group description |
Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days | ||
Reporting group title |
Gonal-f® (Follitropin Alfa)
|
||
Reporting group description |
Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days. | ||
Subject analysis set title |
AFOLIA-150 (Follitropin Alfa) (Per Protocol Population)
|
||
Subject analysis set type |
Per protocol | ||
Subject analysis set description |
Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days; Per Protocol Population
|
||
Subject analysis set title |
Gonal-f® (Follitropin Alfa) (Per Protocol Population)
|
||
Subject analysis set type |
Per protocol | ||
Subject analysis set description |
Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days; Per Protocol Population
|
||
Subject analysis set title |
AFOLIA-150 (Follitropin Alfa) (2nd treatment cycle)
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days; Population with a second treatment cycle
|
||
Subject analysis set title |
Gonal-f® (Follitropin Alfa) (2nd treatment cycle)
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days; Population with a second treatment cycle
|
|
|||||||||||||
End point title |
Number of Oocytes Retrieved (Per Protocol Population) | ||||||||||||
End point description |
As soon as ovulation criteria were reached, HCG was given to trigger ovulation and 34-36 hours later, oocytes were retrieved. If criteria for ovulation triggering could not be reached by FSH stimulation on day 16, treatment was to be stopped.
The equivalence in the number of retrieved oocytes was tested using a pre-determined clinical equivalence margin of +/- 2.9 oocytes
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
34-36 hours after hCG administration and after maximum 16 days of r-hFSH treatment
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Number of Oocytes Retrieved (Per Protocol Pop.) | ||||||||||||
Statistical analysis description |
This study was powered to test equivalence using a two one-sided test (TOST) of the number of oocytes retrieved.
|
||||||||||||
Comparison groups |
AFOLIA-150 (Follitropin Alfa) (Per Protocol Population) v Gonal-f® (Follitropin Alfa) (Per Protocol Population)
|
||||||||||||
Number of subjects included in analysis |
333
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
equivalence [1] | ||||||||||||
P-value |
= 0.0003 [2] | ||||||||||||
Method |
Shuirmann's TOST | ||||||||||||
Confidence interval |
|||||||||||||
Notes [1] - This study was powered to test equivalence using a two one-sided test (TOST) of the number of oocytes retrieved with a power of 90%, an alpha error of 2.5% and a pre-determined clinical equivalence margin of +/-2.9 oocytes for the relevant population. [2] - This study was powered to test equivalence using a two one-sided test (TOST) with a power of 90%, an alpha error of 2.5% and a pre-determined clinical equivalence margin of +/-2.9 oocytes for the relevant population. |
|
|||||||||||||
End point title |
Number of Oocytes Retrieved (Intention-to-treat Population) | ||||||||||||
End point description |
As soon as ovulation criteria were reached, HCG was given to trigger ovulation and 34-36 hours later, oocytes were retrieved. If criteria for ovulation triggering could not be reached by FSH stimulation on day 16, treatment was to be stopped.
The equivalence in the number of retrieved oocytes was tested using a pre-determined clinical equivalence margin of +/- 2.9 oocytes
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
34-36 hours after hCG administration and after maximum 16 days of r-hFSH treatment
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Number of Oocytes Retrieved (Intention to treat) | ||||||||||||
Comparison groups |
AFOLIA-150 (Follitropin Alfa) v Gonal-f® (Follitropin Alfa)
|
||||||||||||
Number of subjects included in analysis |
372
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
equivalence [3] | ||||||||||||
P-value |
= 0.0003 | ||||||||||||
Method |
Shuirmann's TOST | ||||||||||||
Confidence interval |
|||||||||||||
Notes [3] - This study was powered to test equivalence using a two one-sided test (TOST) of the number of oocytes retrieved with a power of 90%, an alpha error of 2.5% and a pre-determined clinical equivalence margin of +/-2.9 oocytes for the relevant population. |
|
||||||||||||||||||||||
End point title |
Number and Size of Follicles ≥ 12 mm at Day 8 of Stimulation | |||||||||||||||||||||
End point description |
The number and size of follicles 12 mm or over in diameter at day 8 of stimulation were evaluated as secondary end-point.
|
|||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||
End point timeframe |
Day 8 of stimulation
|
|||||||||||||||||||||
|
||||||||||||||||||||||
Statistical analysis title |
Number/Size of Follicles ≥ 12 mm day 8 of stimul. | |||||||||||||||||||||
Comparison groups |
AFOLIA-150 (Follitropin Alfa) v Gonal-f® (Follitropin Alfa)
|
|||||||||||||||||||||
Number of subjects included in analysis |
372
|
|||||||||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||||||||
Analysis type |
other | |||||||||||||||||||||
P-value |
= 0.2357 [4] | |||||||||||||||||||||
Method |
Wilcoxon (Mann-Whitney) | |||||||||||||||||||||
Confidence interval |
||||||||||||||||||||||
Notes [4] - Follicles of 12 mm |
||||||||||||||||||||||
Statistical analysis title |
Number/Size of Follicles ≥ 12 mm day 8 of stimul. | |||||||||||||||||||||
Comparison groups |
AFOLIA-150 (Follitropin Alfa) v Gonal-f® (Follitropin Alfa)
|
|||||||||||||||||||||
Number of subjects included in analysis |
372
|
|||||||||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||||||||
Analysis type |
other | |||||||||||||||||||||
P-value |
= 0.1395 [5] | |||||||||||||||||||||
Method |
Wilcoxon (Mann-Whitney) | |||||||||||||||||||||
Confidence interval |
||||||||||||||||||||||
Notes [5] - Follicles of 15 mm |
||||||||||||||||||||||
Statistical analysis title |
Number/Size of Follicles ≥ 12 mm day 8 of stimul. | |||||||||||||||||||||
Comparison groups |
AFOLIA-150 (Follitropin Alfa) v Gonal-f® (Follitropin Alfa)
|
|||||||||||||||||||||
Number of subjects included in analysis |
372
|
|||||||||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||||||||
Analysis type |
other | |||||||||||||||||||||
P-value |
= 0.3992 [6] | |||||||||||||||||||||
Method |
Wilcoxon (Mann-Whitney) | |||||||||||||||||||||
Confidence interval |
||||||||||||||||||||||
Notes [6] - Follicles of 17 mm |
|
|||||||||||||||||||
End point title |
E2 Concentration at Day 8 and at Day of hCG Administration | ||||||||||||||||||
End point description |
The serum concentration of oestradiol was assessed at day 8 and the day of hCG administration.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Day 8 of stimulation and at the day of hCG administration (after max. 16 days of r-FSH treatment)
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Total Dose of r-hFSH Administered | ||||||||||||
End point description |
Total dose of r-hFSH required was assessed.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Day of hCG administration (after maximum 16 days of r-hFSH treatment)
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Total Dose of r-hFSH Administered | ||||||||||||
Comparison groups |
AFOLIA-150 (Follitropin Alfa) v Gonal-f® (Follitropin Alfa)
|
||||||||||||
Number of subjects included in analysis |
372
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
other | ||||||||||||
P-value |
= 0.9638 | ||||||||||||
Method |
Wilcoxon (Mann-Whitney) | ||||||||||||
Confidence interval |
|
||||||||||||||||
End point title |
Quality of Oocytes Retrieved | |||||||||||||||
End point description |
Number of patients with ovum pick-up
|
|||||||||||||||
End point type |
Secondary
|
|||||||||||||||
End point timeframe |
34-36 hours after hCG administration
|
|||||||||||||||
|
||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Fertilisation Rate of Oocytes | ||||||||||||
End point description |
Fertilisation rate was assessed
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
1 day after ovum pick-up
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Embryo Quality: Mean Number of Blastomeres | ||||||||||||
End point description |
Main embryo quality parameter "mean number of blastomeres"
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Day 2 of OPU/fertilisation
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Number of Cryopreserved 2PNs, Embryos/Blastocysts | |||||||||
End point description |
||||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
Day 1, 2, 3 and 5 of OPU/fertilisation
|
|||||||||
|
||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Number of Days of r-hFSH Stimulation | ||||||||||||
End point description |
Mean duration of stimulation was assessed.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
At the day of hCG administration
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Number of Days of r-hFSH Stimulation | ||||||||||||
Comparison groups |
AFOLIA-150 (Follitropin Alfa) v Gonal-f® (Follitropin Alfa)
|
||||||||||||
Number of subjects included in analysis |
372
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
other | ||||||||||||
P-value |
= 0.8926 | ||||||||||||
Method |
Wilcoxon (Mann-Whitney) | ||||||||||||
Confidence interval |
|
||||||||||
End point title |
Number of Patients With Cycle Cancellation | |||||||||
End point description |
Number of patients with cycle cancellation was assessed.
|
|||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
At the end of the study
|
|||||||||
|
||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Number of Patients With Good Response | |||||||||
End point description |
Good response was defined as "patients with an oocyte retrieval of four or more oocytes"
|
|||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
At the end of the study
|
|||||||||
|
||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||
End point title |
Local and Systemic Adverse Events | ||||||||||||||||||||||||
End point description |
Assessment of patients with Ovarian hyperstimulation syndrome (OHSS), patients with OHSS and Anti-Müllerian Hormone (AMH) ≥ 24 pmol/L, patients with dose reduction due to risk of hyperstimulation, patients with coasting due to risk of hyperstimulation and patients with hCG withdrawal due to risk of hyperstimulation.
|
||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||
End point timeframe |
During the study
|
||||||||||||||||||||||||
|
|||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Implantation Rate | ||||||||||||
End point description |
Defined as fetal sac per embryo transferred.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Five to six weeks after oocyte retrieval
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Clinical Pregnancy Rate | |||||||||
End point description |
Presence of at least one intrauterine gestational sac.
|
|||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
Five to six weeks after oocyte retrieval
|
|||||||||
|
||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Ongoing Pregnancy | |||||||||
End point description |
Ongoing pregnancy per embryo transfer. Presence of at least one viable fetus 10 weeks after embryo transfer.
|
|||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
Ten weeks after embryo transfer
|
|||||||||
|
||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Live Birth Rate | |||||||||
End point description |
Patients with liveborn children
|
|||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
After childbirth with questionnaire
|
|||||||||
|
||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Embryo Quality: Absence of Multinucleation | ||||||||||||
End point description |
Main embryo quality parameter "absence of multinucleation" observed.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Day 3
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||
End point title |
Quality of Oocytes Retrieved | |||||||||||||||
End point description |
Number of patients with transferred blastocysts
|
|||||||||||||||
End point type |
Secondary
|
|||||||||||||||
End point timeframe |
At day 4 and 5
|
|||||||||||||||
|
||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Quality of Oocytes Retrieved | ||||||||||||
End point description |
Number of embryos per blastocysts transferred
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Day of transfer
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Clinical Pregnancy Rate (Second Treatment Cycle) | |||||||||
End point description |
Presence of at least one intrauterine gestational sac.
|
|||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
Five to six weeks after oocyte retrieval
|
|||||||||
|
||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Ongoing Pregnancy (Second Treatment Cycle) | |||||||||
End point description |
Ongoing pregnancy per embryo transfer. Presence of at least one viable fetus 10 weeks after embryo transfer.
|
|||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
10 weeks after embryo transfer
|
|||||||||
|
||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||
End point title |
Quality of Oocytes Retrieved | |||||||||||||||||||||
End point description |
The maturity of the cumulus oophorus was assessed.
|
|||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||
End point timeframe |
After oocyte retrieval
|
|||||||||||||||||||||
|
||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||
End point title |
Quality of Oocytes Retrieved | |||||||||||||||||||||
End point description |
The nuclear maturity was assessed (Germinal vesicle, Metaphase I, Metaphase II).
|
|||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||
End point timeframe |
After oocyte retrieval
|
|||||||||||||||||||||
|
||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Study period plus 30 days
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
14.1
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
AFOLIA-150 (Follitropin Alfa)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Gonal-f® (Follitropin Alfa)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Follitropin alfa: 150IU per day subcutaneously for a maximum of 16 days. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 0% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported | |||
Online references |
|||
http://www.ncbi.nlm.nih.gov/pubmed/25735918 |